Consolidation radiotherapy refusal in stage I-II Hodgkin lymphoma: sociodemographic determinants and impact on survival outcomes.
[BACKGROUND] Consolidation radiotherapy following chemotherapy represents the standard of care for stage I-II classical Hodgkin lymphoma, yet treatment adherence varies in clinical practice.
- p-value p < 0.01
- HR 0.630
- 연구 설계 cohort study
APA
Loap P, Kirova Y (2026). Consolidation radiotherapy refusal in stage I-II Hodgkin lymphoma: sociodemographic determinants and impact on survival outcomes.. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]. https://doi.org/10.1007/s00066-026-02524-1
MLA
Loap P, et al.. "Consolidation radiotherapy refusal in stage I-II Hodgkin lymphoma: sociodemographic determinants and impact on survival outcomes.." Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026.
PMID
41973237
Abstract
[BACKGROUND] Consolidation radiotherapy following chemotherapy represents the standard of care for stage I-II classical Hodgkin lymphoma, yet treatment adherence varies in clinical practice. No previous study has systematically examined the patient characteristics associated with radiotherapy refusal or its impact on survival outcomes. We aimed to identify determinants of consolidation radiotherapy refusal and evaluate its consequences on cause-specific (CSS) and overall survival (OS).
[METHODS] We conducted a retrospective cohort study using the SEER database (2024 submission, 17 registries) analyzing patients diagnosed with stage I-II Hodgkin lymphoma between 2000 and 2022 who received chemotherapy with indicated consolidation radiotherapy. Patients were categorized based on radiotherapy receipt versus refusal. Chi-square tests compared patient characteristics between groups. Kaplan-Meier methods assessed survival outcomes, and Cox proportional hazards models identified prognostic factors among radiotherapy recipients.
[RESULTS] Among 9150 patients, 141 (1.5%) refused consolidation radiotherapy despite medical indication. Radiotherapy refusal was significantly associated with non-white ethnicity (35.5% vs. 29.9%, p < 0.01) and residence in large metropolitan areas (> 1 million population; 68.8% vs. 59.0%, p < 0.01), with a trend toward higher refusal among women (56.7% vs. 49.0%, p = 0.08). Radiotherapy refusal was significantly associated with inferior survival outcomes: 10-year OS was 83.3% versus 90.0% (p = 0.0014) and 10-year CSS was 90.4% versus 95.0% (p = 0.029) for refusers versus recipients, respectively. Among radiotherapy recipients, multivariable analysis revealed significant socioeconomic disparities, with living with a partner (HR = 0.630, p < 0.001) and higher household income (HR = 0.750, p < 0.001) as protective factors for CSS.
[CONCLUSION] Non-white ethnicity and residence in a large metropolitan area are risk factors for consolidation radiotherapy refusal in stage I-II Hodgkin lymphoma, with significant adverse associations with survival outcomes. Substantial socioeconomic disparities exist in outcomes among treated patients. These findings highlight the need for targeted educational interventions and culturally sensitive counseling to ensure equitable access to optimal care in this highly curable disease.
[METHODS] We conducted a retrospective cohort study using the SEER database (2024 submission, 17 registries) analyzing patients diagnosed with stage I-II Hodgkin lymphoma between 2000 and 2022 who received chemotherapy with indicated consolidation radiotherapy. Patients were categorized based on radiotherapy receipt versus refusal. Chi-square tests compared patient characteristics between groups. Kaplan-Meier methods assessed survival outcomes, and Cox proportional hazards models identified prognostic factors among radiotherapy recipients.
[RESULTS] Among 9150 patients, 141 (1.5%) refused consolidation radiotherapy despite medical indication. Radiotherapy refusal was significantly associated with non-white ethnicity (35.5% vs. 29.9%, p < 0.01) and residence in large metropolitan areas (> 1 million population; 68.8% vs. 59.0%, p < 0.01), with a trend toward higher refusal among women (56.7% vs. 49.0%, p = 0.08). Radiotherapy refusal was significantly associated with inferior survival outcomes: 10-year OS was 83.3% versus 90.0% (p = 0.0014) and 10-year CSS was 90.4% versus 95.0% (p = 0.029) for refusers versus recipients, respectively. Among radiotherapy recipients, multivariable analysis revealed significant socioeconomic disparities, with living with a partner (HR = 0.630, p < 0.001) and higher household income (HR = 0.750, p < 0.001) as protective factors for CSS.
[CONCLUSION] Non-white ethnicity and residence in a large metropolitan area are risk factors for consolidation radiotherapy refusal in stage I-II Hodgkin lymphoma, with significant adverse associations with survival outcomes. Substantial socioeconomic disparities exist in outcomes among treated patients. These findings highlight the need for targeted educational interventions and culturally sensitive counseling to ensure equitable access to optimal care in this highly curable disease.
같은 제1저자의 인용 많은 논문 (5)
- Optimizing bridging radiotherapy prior to CAR-T cell therapy: An evidence-based approach.
- Genomic analysis of radiosensitivity in breast cancer : Identifying pathological determinants and assessing genomic-adjusted radiation dose (GARD) for personalized dose escalation.
- First Comprehensive Characterization of Lip Lymphoma: A Population-Based Study.
- Toward genomic personalization of breast cancer radiotherapy: foundations, challenges, and a roadmap for clinical integration.
- Feasibility of a third breast-conserving treatment in ipsilateral breast cancer recurrence: A retrospective population-based analysis.